A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain
Overview
The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Double (Participant, Investigator)
- Study Primary Completion Date: February 2015
Detailed Description
We conduct the study in Cukurova University Faculty of Medicine Research Hospital after obtaining ethics committee approval and patient's informed consent. Patients with cancer pain are allocated into two group to receive Patient Controlled Analgesia with morphine or morphine plus dexmedetomidine.
Interventions
- Drug: Morphine
- Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
- Drug: Morphine plus dexmedetomidine
- Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
Arms, Groups and Cohorts
- Active Comparator: Control
- Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
- Active Comparator: Morphine plus dexmedetomidine
- Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
Clinical Trial Outcome Measures
Primary Measures
- Morphine consumption (mg)
- Time Frame: 24 hours
- cumulative morphine consumption for 24 hours
Secondary Measures
- Pain score
- Time Frame: 24 hours
- visual analog scale to assess pain degree
Participating in This Clinical Trial
Inclusion Criteria
- patients with chronic cancer pain – between 20-80 years old age Exclusion Criteria:
- the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal) – psychiatric or neurologic disease – unable to communicate verbally – nausea and vomiting – patient's refusal
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Cukurova University
- Provider of Information About this Clinical Study
- Principal Investigator: Ersel GULEC, Ersel Gulec – Cukurova University
- Overall Official(s)
- Selcuk Gök, M.D, Principal Investigator, Cukurova University
References
Blaudszun G, Lysakowski C, Elia N, Tramer MR. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012 Jun;116(6):1312-22. doi: 10.1097/ALN.0b013e31825681cb.
Citations Reporting on Results
Lin TF, Yeh YC, Lin FS, Wang YP, Lin CJ, Sun WZ, Fan SZ. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth. 2009 Jan;102(1):117-22. doi: 10.1093/bja/aen320. Epub 2008 Nov 5.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.